Abstract
In mononeuropathic rats submitted to a C-fiber reflex responses paradigm, repeated administration (five successive injections every half-life) of 10 mg/kg, s.c. of venlafaxine, but not of 2.5 mg/kg, s.c., a mixed monoamine reuptake inhibitor with preferential inhibitory activity in 5-HT reuptake, induced a progressive reduction of spinal wind-up. Repeated co-administration of the selective 5-HT1A receptor antagonist WAY 100,635 i.c.v. (50 microg/injection) significantly increased the effect of venlafaxine s.c., indicating that venlafaxine-induced inhibition of spinal wind-up in mononeuropathic rats is potentiated by blockade of central 5-HT1A receptors.
Copyright 2004 Elsevier B.V.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Cyclohexanols / pharmacology*
-
Male
-
Nerve Fibers, Unmyelinated / drug effects
-
Peripheral Nervous System Diseases / pathology*
-
Piperazines / pharmacology
-
Pyridines / pharmacology
-
Rats
-
Rats, Sprague-Dawley
-
Receptor, Serotonin, 5-HT1A / drug effects*
-
Reflex / drug effects
-
Selective Serotonin Reuptake Inhibitors / pharmacology*
-
Serotonin Antagonists / pharmacology
-
Spinal Cord / cytology*
-
Spinal Cord / drug effects
-
Venlafaxine Hydrochloride
Substances
-
Cyclohexanols
-
Piperazines
-
Pyridines
-
Serotonin Antagonists
-
Serotonin Uptake Inhibitors
-
Receptor, Serotonin, 5-HT1A
-
N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridinyl)cyclohexanecarboxamide
-
Venlafaxine Hydrochloride